


Oncological Treatment of Upper GI Cancer

Pathway of Care

Kent & Medway Cancer Collaborative



Publication date	July 2021
Expected review date	July 2022
Version number	21
Version status	Final

TABLE OF CONTENTS

1.0	INTRODUCTION	4
1.1	Genomic Testing	4
1.1.1	NTRK Fusion Positive	4
1.1.2	Microsatellite Instability (MSI-H) or Mismatch Repair Deficiency	4
1.2	Choice of Platinum / Fluoropyrimidine (or Raltitrexed)	4
2.0	OESOPHAGEAL CANCER AND TYPE 1/2 GASTRO-OESOPHAGEAL JUNCTION CANCER	5
2.1	Squamous cell carcinoma of the oesophageal cancer	5
2.1.1	Neo-Adjuvant Chemoradiation	5
2.1.2	Radical Chemotherapy	5
2.2	Adenocarcinoma of the Lower Oesophagus or Type 1 Or 2 Gastro-Oesophageal Junction Cancer	6
2.2.1	Peri-Operative Chemotherapy	6
2.2.2	Neo-Adjuvant Chemoradiation	6
2.2.3	Adjuvant Chemoradiation	7
2.3	Adjuvant Chemotherapy for Patients Receiving Upfront Surgery (i.e. Unsuitable for Treatment as per 2.1 and 2.2)	7
2.4	Palliative Radiotherapy	7
2.5	Palliative Chemotherapy	7
2.5.1	First Line Palliative Chemotherapy	8
2.5.2	Second Line Palliative Chemotherapy	8
3.0	GASTRIC / TYPE 3 GASTRO-OESOPHAGEAL JUNCTION CANCER	9
3.1	Peri-Operative Chemotherapy	9
3.2	Adjuvant Chemoradiation	9
3.3	Adjuvant Chemotherapy for Patients Receiving Upfront Surgery	10
3.4	Palliative Chemotherapy	10
3.4.1	First Line	10
3.4.2	Subsequent (2 nd line and Beyond) Palliative Chemotherapy	11
3.5	Palliative Radiotherapy	11
4.0	PANCREATIC ADENOCARCINOMA	12
4.1	Neo-Adjuvant	12
4.2	Adjuvant Chemotherapy	12
4.3	Adjuvant Chemoradiation (After Completion of Adjuvant Chemotherapy)	12
4.4	Chemoradiation for Locally Advanced Disease	12
4.5	Palliative Chemotherapy	13
4.5.1	First Line	13
4.5.2	Second Line Palliative Chemotherapy	13
4.6	Palliative Radiotherapy	13

5.0	CHOLANGIOCARCINOMA / GALL BLADDER CARCINOMA	14
5.1	Adjuvant Chemotherapy	14
5.2	Palliative Chemotherapy	14
6.0	HEPATOCELLULAR CARCINOMA.....	15
6.1	Localised Disease	15
6.2	Palliative Chemotherapy	15
7.0	SMALL BOWEL CARCINOMA	16
7.1	Adjuvant Chemotherapy	16
7.2	Palliative Chemotherapy Indications	16
8.0	GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS.....	17
8.1	Adjuvant Therapy	17
8.2	Palliative Systemic Anti-Cancer Therapy	17
9.0	GASTROINTESTINAL STROMAL TUMOURS	19
9.1	Adjuvant Therapy	19
9.2	First Line Metastatic Therapy	19
9.3	Second Line Metastatic Therapy	19
9.4	Third Line Metastatic Therapy	19
10.0	GUIDELINES ON THE MANAGEMENT OF DRUG-SPECIFIC TOXICITY	20
10.1	DPD Testing.....	20
10.2	Uridine Triacetate	20
11.0	APPENDIX A: CLINICAL TRIALS.....	21
12.0	APPENDIX B: KMCC GUIDELINES ON MANAGING CARDIAC TOXICITY FOR PATIENTS RECEIVING TRASTUZUMAB	21
13.0	PERSONNEL AND CONTACT INFORMATION.....	22
14.0	GLOSSARY.....	22
15.0	DOCUMENT ADMINISTRATION.....	23

1.0 INTRODUCTION

This document has been written to provide guidance on the treatment of Upper GI cancer in the Kent & Medway Cancer Collaborative

Radiotherapy schedules are as defined in the Kent Oncology Centre Quality System Clinical Protocols (Disease Management and Radiotherapy Protocols).

See network chemotherapy prescribing proformas for details of chemotherapy / anti-cancer regimens.

All patients will be considered for entry into a clinical trial ([see appendix A](#)).

All patients should be discussed within a multidisciplinary team meeting before commencing initial treatment.

Please note, some of the drugs/doses recommended within this document are outside of the U.K. licensed marketing authorisation.

To allow for flexibility in the management of cancer during the COVID-19 pandemic, NHS England has endorsed interim treatment regimens for some cancer medicines. This is to reduce the need for direct patient contact for administration of drugs and to minimise potential side effects that make people more susceptible to viral infections and other ill-health effects that may add pressure to the health system. These interim treatment regimens can be access here:

<https://www.nice.org.uk/guidance/ng161/chapter/7-Modifications-to-usual-service#interim-nhs-england-treatment-regimens>

1.1 Genomic Testing

The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access a test. This is in development; molecular testing for upper GI cancer in Kent will evolve in line with this guidance.

1.1.1 NTRK Fusion Positive

Patients with NTRK gene fusion may be considered for entrectinib or larotrectinib in line with commissioning criteria.

1.1.2 Microsatellite Instability (MSI-H) or Mismatch Repair Deficiency

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

1.2 Choice of Platinum / Fluoropyrimidine (or Raltitrexed)

Where indicated in the guidelines, CX is considered standard treatment. The following drugs may be used as alternatives in the following situations:

- Consider substitution of Cisplatin with Carboplatin (AUC 5) if renal (GFR 30-60mls/min) or auditory dysfunction.
- Consider substitution of Capecitabine with 5FU 200 mg/m²/day continuous infusion if unable to swallow tablets.
- Consider substitution of Fluoropyrimidine with Raltitrexed in the event of Fluoropyrimidine induced chest pain.

2.0 OESOPHAGEAL CANCER AND TYPE 1/2 GASTRO-OESOPHAGEAL JUNCTION CANCER

Definitions of gastro-oesophageal junction cancers:

- Type I: adenocarcinoma of the distal oesophagus (epicentre of lesion 1-5 cm above GOJ)
- Type II: adenocarcinoma of the cardia (epicentre of lesion up to 1 cm above and 2 cm below GOJ)
- Type III: sub-cardial type adenocarcinoma (epicentre of lesion 2-5 cm below GOJ)

2.1 Squamous cell carcinoma of the oesophageal cancer

2.1.1 Neo-Adjuvant Chemoradiation

Neo-adjuvant chemoradiation may be considered for selected oesophageal cancer patients and should be agreed at MDT

Indications:

- Potentially operable oesophageal cancer
- Performance status 0-1
- T3 N 0-2. Max 5cm tumour length
- T4 if only involving diaphragmatic crus.
- All nodes above diaphragm
- Minimal comorbidity
- Adeno/Squamous carcinoma
- Agreed at MDT

Chemoradiotherapy regimen:

- Paclitaxel 50mg/m² + Carboplatin AUC 2 on days 1, 8, 15, 22 and 29.
- Concurrent radiotherapy as defined in the Kent Oncology Centre Quality Systems Clinical Protocols (Disease management and Radiotherapy Protocols).

2.1.2 Radical Chemotherapy

Indications:

- T4N0-1M0
- T1-3N0-1M0 unsuitable/unwilling for surgery (may be considered in preference to surgery for squamous cell carcinoma)

Treatment

- Primary chemotherapy with CX, CarboX, CarboF, CF x 3-4 cycles
- Chemoradiation with Cisplatin plus 5FU continuous infusion (CF) or Cisplatin plus Capecitabine (CX) x 5 weeks (single agent Capecitabine or infused 5-fluorouracil with concurrent radiotherapy as above may be considered for less fit patients). Carboplatin + paclitaxel to be used in selected patients who are unlikely to tolerate Cisplatin / Fluoropyridimine.

Concurrent radiotherapy as defined in the Kent Oncology Centre Quality Systems Clinical Protocols (Disease management and Radiotherapy Protocols).

Tumour assessment

- OGD, CT scan, EUS pre-treatment. Consider PET/CT scan and staging laparoscopy.
- CT scan after 4 cycles of chemotherapy or earlier if no symptom response.
- CT scan and OGD (plus biopsy) 12 weeks post completion of chemoradiation
- Consider surgical resection if residual carcinoma present.

For patients who may be suitable for salvage surgery, 3 monthly OGD and CT scan for 2 years, then 6-monthly for year 3 then annually to 5 years.

2.2 Adenocarcinoma of the Lower Oesophagus or Type 1 Or 2 Gastro-Oesophageal Junction Cancer

2.2.1 Peri-Operative Chemotherapy

Indications:

Gastro-oesophageal junction adenocarcinoma considered suitable for curative resection:

- T1, N1-3, M0
- T2a, N0-3, M0
- T2b, N0-3, M0
- T3, N0-3, M0

Treatment

- FLOT (only for patients with PS 0-1) x 4 cycles pre-operative and 4 cycles post-operative
- CX, CF, Carbo X, CarboF, OX, OF x 3 cycles preoperative and 3 cycles post-operative.

Tumour assessment

- OGD, CT scan, laparoscopy pre-treatment. EUS for tumours involving oesophago-gastric junction
- CT scan post 3 cycles
- CT scan post 6 cycles

Surgery

Surgery should be performed 4-6 weeks after completion of the third cycle of chemotherapy

2.2.2 Neo-Adjuvant Chemoradiation

Neo-adjuvant chemoradiation may be considered for selected oesophageal cancer patients and should be agreed at MDT

Indications

- Potentially operable oesophageal cancer
- Performance status 0-1
- T3 N 0-2. Max 5cm tumour length
- T4 if only involving diaphragmatic crus.
- All nodes above diaphragm
- Minimal comorbidity
- Adeno/Squamous carcinoma
- Agreed at MDT

Chemoradiotherapy regimen

- Paclitaxel 50mg/m² + Carboplatin AUC 2 on days 1, 8, 15, 22 and 29.

Concurrent radiotherapy as defined in the Kent Oncology Centre Quality Systems Clinical Protocols (Disease management and Radiotherapy Protocols).

2.2.3 Adjuvant Chemoradiation

Adjuvant chemoradiation can be considered for patient with R1 or R2 resection.

Chemoradiation with Cisplatin plus 5FU continuous infusion (CF) or Cisplatin plus Capecitabine (CX) x 5 weeks (single agent Capecitabine or infused 5-fluorouracil with concurrent radiotherapy as above may be considered for less fit patients).

Concurrent radiotherapy as defined in the Kent Oncology Centre Quality Systems Clinical Protocols (Disease management and Radiotherapy Protocols).

2.3 Adjuvant Chemotherapy for Patients Receiving Upfront Surgery (i.e. Unsuited for Treatment as per 2.1 and 2.2)

Indications

For patients undergoing surgery for oesophageal carcinoma without pre-operative chemotherapy, there is no proven role for adjuvant chemotherapy. However, in the presence of adverse risk factors (nodal involvement, positive surgical excision margins), adjuvant chemotherapy may be considered on an individual case basis.

Treatment

- Squamous: 6 cycles of CX, CarboX, CF or CarboF
- Adenocarcinoma: 8 cycles of FLOT, or 6 cycles of CX, CarboX, CF or CarboF

Patients with positive surgical margins may also benefit from postoperative chemoradiation with continuous infusion 5FU 200 mg/m²/day or Capecitabine 1250 mg/m²/day with concurrent radiotherapy 50Gy in 25 fractions.

Tumour assessment

End of treatment CT scan

2.4 Palliative Radiotherapy

Palliative external beam radiotherapy to the oesophagus can be offered for symptom control and for consolidating a good response to chemotherapy. The dose and fractionation depends on the stage of disease and performance status of the patient (refer to radiotherapy protocols). Oesophageal brachytherapy can be offered for re-treatment for symptom control.

2.5 Palliative Chemotherapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

2.5.1 First Line Palliative Chemotherapy

Indications

- Metastatic disease
- Localised or locally advanced disease and patient unsuitable for or unwilling to receive 24 weeks combination treatment of Oxaliplatin, Fluoropyrimidine, surgery or radical chemoradiation
- Performance status 0-2

Treatment

- 6-8 cycles of:
 - OX
 - OF
- Or alternatively if oxaliplatin is unsuitable or squamous carcinoma:
 - CX
 - CF
 - Carbo X
 - CarboF
- Carboplatin and paclitaxel every 3 weeks.
- CX, CF, CarboX or CarboF with trastuzumab for Her-2 positive adenocarcinoma of the gastro oesophageal junction.

Tumour assessment

- CT scan pre-treatment
- CT scan post 3-4 cycles (consider suitability for surgery if locally advanced disease down-staged)
- CT scan post 6-8 cycles

2.5.2 Second Line Palliative Chemotherapy

Indications

Patients remaining of good performance status (0-1) following disease progression after first line palliative chemotherapy or radical chemoradiation.

Treatment

- (i) Nivolumab for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy.
- (ii) Disease-free interval from completion of previous chemotherapy > 6 months; consider Platinum/ fluoropyrimidine based chemotherapy.
- (iii) Disease-free interval < 6 months; There is evidence for-Irinotecan/5FU/Leucovorin (FOLFIRI regimen) or single agent Docetaxel or weekly Paclitaxel (funding approval required for all 3 regimens). Consider referral for phase I/II clinical trials.
- (iv) Irinotecan & Capecitabine can be considered in selected patients. (Algorithm deviation)
- (v) Brachytherapy will be considered for patients previously treated with EBR that have local progression and symptoms such as dysphagia and pain.

Tumour assessment

CT scan every 2-3 months

3.0 GASTRIC / TYPE 3 GASTRO-OESOPHAGEAL JUNCTION CANCER

3.1 Peri-Operative Chemotherapy

Indications

Gastric or oesophago-gastric junction adenocarcinoma considered suitable for curative resection:

- T1, N1-3, M0
- T2a, N0-3, M0
- T2b, N0-3, M0
- T3, N0-3, M0

Treatment

- FLOT (only for patients with PS 0-1) x 4 cycles pre-operative and 4 cycles post-operative
- CX, CF, Carbo X, CarboF, OX, OF x 3 cycles preoperative and 3 cycles post-operative

Tumour assessment

- OGD, CT scan, laparoscopy pre-treatment. EUS for tumours involving oesophago-gastric junction
- CT scan post 3 cycles
- CT scan post 6 cycles

Surgery

Surgery should be performed 4-6 weeks after completion of the third cycle of chemotherapy

3.2 Adjuvant Chemoradiation

Indications

The Intergroup 0116 study demonstrated a survival benefit for patients who had undergone a microscopically complete surgical resection of gastric adenocarcinoma who received adjuvant chemoradiation therapy compared with no adjuvant treatment.

Adjuvant chemoradiation should therefore be considered a treatment option for these patients, particularly if there is considered to be a high risk of local failure (e.g. no/ limited lymphadenectomy performed, close or microscopically involved surgical excision margins).

Treatment

All cases to be discussed within an MDM. 3 cycles CX, CF, CarboX, CarboF then Capecitabine or infused 5-fluoruracil with radiotherapy for 5 weeks OR chemoradiation without prior chemotherapy (Capecitabine or infused 5-fluoruracil with radiotherapy for 5 weeks).

Tumour assessment

CT scan 3 months post completion of chemoradiation

3.3 Adjuvant Chemotherapy for Patients Receiving Upfront Surgery

Indications

The role of adjuvant postoperative chemotherapy following resection of gastric cancer remains unclear. A large number of clinical trials have addressed this question, the majority of which have not demonstrated a benefit from treatment. However, many of these trials were of poor methodologic quality, were underpowered to demonstrate a small but clinically relevant survival advantage, and employed chemotherapy regimens with limited activity in the advanced disease setting. Several meta-analyses of these data have been undertaken, which demonstrate a small benefit for adjuvant chemotherapy over no post-operative treatment, with a hazard ratio for survival between 0.72 and 0.88. However, when analysed separately, the positive effect of chemotherapy on survival was confined to Asian trials, with no benefit observed in Western studies.

Therefore, at present, adjuvant chemotherapy should not be recommended routinely. However, in the presence of adverse risk factors (nodal involvement, positive surgical excision margins), adjuvant chemotherapy may be considered on an individual case basis.

Treatment

- Squamous: 6 cycles of CX, CarboX, CF or CarboF
- Adenocarcinoma: 8 cycles of FLOT, or 6 cycles of CX, CarboX, CF or CarboF

Tumour assessment

CT scan end of treatment

3.4 Palliative Chemotherapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

3.4.1 First Line

Indications

- Metastatic disease
- Locally advanced disease
- Localised disease and patient unsuitable for or unwilling to receive 24 weeks combination treatment of Oxaliplatin, Fluoropyrimidine or surgery
- Performance status 0-2

Treatment

- 6-8 cycles of:
 - OX
 - OF
- Or alternatively if oxaliplatin is unsuitable:
 - CX
 - CF
 - Carbo X
 - CarboF

For HER-2 positive patients (IHC3+)

CX or CF x 6 cycles + trastuzumab until progressive disease in line with NICE TA 208. (N.B. may also be used for patients with HER 2 overexpression as defined by IHC2-positive and a confirmatory SISH or FISH result who have not received prior anti-cancer treatment for their metastatic disease, funding streams for FISH testing are currently under discussion).

Tumour assessment

- CT scan pre-treatment
- CT scan post 3-4 cycles (consider suitability for surgery if locally advanced disease down-staged)
- CT scan post 6-8 cycles

3.4.2 Subsequent (2nd line and Beyond) Palliative Chemotherapy

Indications

Patients remaining of good performance status (0-1) following disease progression after first line palliative chemotherapy or peri-operative chemotherapy.

Treatment

- (i) Disease-free interval from completion of previous chemotherapy > 6 months; consider Platinum/ fluoropyridimine based chemotherapy.
- (ii) Disease-free interval < 6 months; Consider Irinotecan/5FU/Leucovorin (FOLFIRI regimen), single agent Docetaxel, weekly Paclitaxel or Ramucirumab with paclitaxel (funding approval required for all 4 regimens).

Consider referral for phase I/II clinical trials.

Tumour assessment

CT scan every 2-3 months

3.5 Palliative Radiotherapy

Palliative radiotherapy to the stomach can be offered for haemostasis if surgery is not indicated, or for pain management.

4.0 PANCREATIC ADENOCARCINOMA

4.1 Neo-Adjuvant

Treatment

- Gemcitabine
- PS 0-1 modified folfirinox* or gemcitabine & capecitabine*

*NB Use palliative regimen.

4.2 Adjuvant Chemotherapy

Indications

Macroscopically completely resected pancreatic adenocarcinoma

Treatment

- Gemcitabine or Gemcitabine & Capecitabine depending on PS
- Adjuvant Modified Folfirinox x 12 cycles

Tumour assessment

- Post treatment CT scan
- Monitor Ca19.9 each cycle

4.3 Adjuvant Chemoradiation (After Completion of Adjuvant Chemotherapy)

Consider adjuvant chemoradiation in selected patients with R1 resection.

4.4 Chemoradiation for Locally Advanced Disease

Indications

- Pancreatic adenocarcinoma confined to pancreas +/- local nodes not amenable to surgical resection
- Performance status 0-1

Treatment

- All patients should initially be offered 6 months of chemotherapy with a first line advanced disease protocol (see [section 3.3](#))
- If disease remains localized and amenable to radical chemoradiation, this may be considered as follows:
 - Capecitabine with concurrent radiotherapy.

Tumour assessment

- Pre-treatment CT scan (plus MRI/ EUS/ laparoscopy as required to determine inoperability)
- CT scan following 12 and 24 weeks Gemcitabine chemotherapy and 12 weeks after completion of chemoradiotherapy.

4.5 Palliative Chemotherapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

4.5.1 First Line

Indications

- Locally advanced inoperable adenocarcinoma of the pancreas
- Metastatic disease
- Performance status 0-2

Treatment for locally advanced disease:

- Gemcitabine
- PS 0-1 Palliative modified folfirinox or gemcitabine & capecitabine
- Chemoradiation

Treatment for metastatic disease:

- Albumin bound paclitaxel with gemcitabine can be considered only if other irinotecan or oxaliplatin based combination chemotherapies are unsuitable and the patient would otherwise have gemcitabine monotherapy. (Patients should be PS 0-1 and should have had no previous chemotherapy for early disease unless given as a radiation sensitiser in the adjuvant setting and completed at least 6 months previously).
- Folfirinox
- PS 1-2 - Gemcitabine until progression or intolerance

Patients with prolonged disease control (> 6 months) following adjuvant Gemcitabine who remain of good performance status upon disease relapse may be considered for Gemcitabine re-challenge or Fluoropyrimidine-based therapy.

Tumour assessment

- Pre-treatment CT scan
- CT scan after 12 weeks
- CT scan after 24 weeks
- Ca19.9 levels every 4 weeks

4.5.2 Second Line Palliative Chemotherapy

Treatment

Clinicians' choice of fluoropyrimidine/platinum or gemcitabine- based therapy depending on prior therapy.

Tumour assessment

CT scan pre-treatment and every 9-12 weeks during therapy

4.6 Palliative Radiotherapy

Palliative radiotherapy to the pancreas can be offered for pain control if other measures have failed such as opiates and nerve blocks. It can also be useful for haemostasis if the tumour is involving duodenum.

5.0 CHOLANGIOCARCINOMA / GALL BLADDER CARCINOMA

5.1 Adjuvant Chemotherapy

Treatment

Consider Capecitabine as per BILCAP trial or entry to clinical trial

Tumour assessment

- Post-operative CT scan
- CT scan post 6 cycles chemotherapy
- Monitor Ca19.9 each cycle

5.2 Palliative Chemotherapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

Indications

- Locally advanced inoperable cholangiocarcinoma
- Metastatic disease
- Performance status 0-2

Treatment

- Gemcitabine plus Cisplatin x 6-8 cycles (carboplatin may be used in patients who cannot tolerate cisplatin)
- Gemcitabine for a total of up to 24 weeks
- 6-8 cycles of:
 - OX
 - OF

Pemigatinib may be considered for fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy

Tumour assessment

- Pre-treatment CT scan
- CT scan after 12 weeks
- CT scan after 24 weeks
- Ca19.9 levels every 4 weeks

6.0 HEPATOCELLULAR CARCINOMA

6.1 Localised Disease

All patients should be referred to Kings College Hospital for consideration of resection or chemoembolisation.

6.2 Palliative Chemotherapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

Indications

- Locally advanced disease not amenable to loco-regional therapy
- Metastatic disease
- Performance status 0-2
- Child-Pugh status A (or low burden Child-Pugh B for sorafenib)

Treatment

- Atezolizumab and bevacizumab for 1st line systemic treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma.
- Sorafenib for 1st line, or 2nd line if atezolizumab and bevacizumab has been given first line, in patients with Child–Pugh A disease.
- Lenvatinib for 1st line, or 2nd line if atezolizumab and bevacizumab has been given first line, treatment in patients with Child–Pugh A disease.
- Regorafenib for the 2nd line systemic therapy of Child-Pugh A previously treated with sorafenib.

Tumour assessment

- CT scan pre-chemotherapy
- CT scan post 3 cycles
- CT scan post 6 cycles
- AFP levels before each cycle

7.0 SMALL BOWEL CARCINOMA

7.1 Adjuvant Chemotherapy

Indications

There is no established role for adjuvant chemotherapy, but for selected patients with poor prognostic features, 6-8 cycles of OX, OF or OT may be considered.

7.2 Palliative Chemotherapy Indications

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

Advanced disease not amenable to surgical resection
Performance status 0-2

Treatment

There is no standard treatment regimen.

Suitable patients may be considered for

- 6-8 cycles of:
 - OX
 - OF
- Or alternatively if oxaliplatin is unsuitable:
 - CX
 - CF
 - Carbo X
 - CarboF

Tumour assessment

- CT scan pre-treatment
- CT scan post 3-4 cycles
- CT scan post 6-8 cycles

8.0 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS

8.1 Adjuvant Therapy

Indications

There is no role for adjuvant therapy following surgical resection of gastroenteropancreatic neuroendocrine tumours.

Goblet cell carcinoid tumours of the appendix (adenocarcinoids) with lymph node involvement or T3N0 disease should be considered for adjuvant chemotherapy with 8 cycles of Capecitabine.

8.2 Palliative Systemic Anti-Cancer Therapy

In selected cases patients with metastatic or locally advanced and unresectable upper gastrointestinal cancers, will be tested for microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) and where appropriate treatment with nivolumab will be considered (interim COVID regimen).

A number of therapeutic options exist as follows:

- (i) Surgical resection of hepatic metastatic disease (Refer to Kings College Hospital)
- (ii) Embolisation (refer to Kings College Hospital) or radiofrequency ablation of hepatic metastatic disease (Refer to Maidstone Hospital or Kings College Hospital)
- (iii) Somatostatin analogue therapy
- (iv) Radiolabeled MIBG/ octreotide (Funding approval required.)
 - Peptide receptor radionuclide therapy (Lutetium 177 octreotate) should be considered for the treatment of unresectable or metastatic, progressive, well differentiated and somatostatin receptor positive gastroenteropancreatic neuroendocrine carcinoma.
- (v) Selective internal radiotherapy (SIRT) (Refer to Kings NET MDT) Funding approval required.
- (vi) Systemic anti-cancer therapy

Indications

Active therapy should be considered for:

- (i) Symptomatic metastatic disease (e.g. symptoms of the carcinoid syndrome, local symptoms due to tumour mass/ invasion such as pain, haemoptysis, cough, biliary obstruction)
- (ii) Rapidly progressive metastatic disease

Treatment

The choice of treatment will be dictated by the clinical situation.

(i) Somatostatin analogue therapy

Highly symptomatic patients should be commenced on a short acting preparation initially (e.g. octreotide 50 mcg s/c bd increased as necessary to 200 mcg tds SC)

Responding patients should then be converted onto a long acting preparation (e.g. Sandostatin LAR 20 mg IM 4-weekly, increased if necessary to 30 mg IM 4-weekly or Somatuline autogel 60 mg s/c 4-weekly, increased if necessary to 120 mg s/c 4-weekly)

(ii) Systemic anti-cancer therapy

There is no standard chemotherapy regimen for this disease. Patients with increased likelihood of response to chemotherapy are those with poorly differentiated tumours, particularly those with a high proliferative rate (Ki67>10%), pancreatic neuroendocrine carcinomas.

The following regimens may be considered.

- Streptozocin plus Capecitabine x 6 cycles
- Streptozocin plus Doxorubicin x 4 cycles
- Streptozocin plus Capecitabine plus Cisplatin x 6-8 cycles
- Carboplatin plus Etoposide x 6 cycles
- Capecitabine plus Temozolomide x 6-8 cycles

There is increasing evidence for the use of targeted therapies in neuroendocrine tumours.

Sunitinib may be considered as 1st, 2nd or 3rd line treatment for well differentiated pancreatic neuroendocrine tumours.

Everolimus may be considered for well differentiated pancreatic, non-functioning gastrointestinal or lung neuroendocrine tumours.

Tumour assessment

Baseline CT scan, octreotide scan, MIBG scan, 24-hour urinary 5-HIAA and VMA, investigation of neuropeptide hormone secretion as clinically indicated, fasting gut hormone profile including chromogranin A and B.

Repeat CT scan and 24-hour urinary 5-HIAA and serum chromogranin A every 3-12 months depending on rate of disease growth.

Repeat CT scan every 12 weeks while receiving cytotoxic chemotherapy

9.0 GASTROINTESTINAL STROMAL TUMOURS

9.1 Adjuvant Therapy

Imatinib 400mg od is recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery for KIT (CD117) -positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 criteria (based on tumour size, location and mitotic rate).

9.2 First Line Metastatic Therapy

Patients presenting with advanced inoperable disease should have tumour specimens sent to the Royal Marsden Hospital for mutational analysis, wild-type c-kit and PDGRFRA should be referred for NTRK fusion analysis.

Imatinib 400mg daily is currently considered standard therapy for all patients. However, for patients with exon 9 c-kit mutations or wild type, there is emerging evidence for a benefit from higher initial Imatinib doses e.g. 600-800mg daily.

Monitoring for patients receiving imatinib

The occurrence of toxicity following institution of imatinib is unpredictable. The following schedule of assessments should be undertaken, with clinical assessment, FBC, U+E and LFT performed at each of 2 weeks, 4 weeks, 8 weeks, 12 weeks then 3 monthly thereafter.

Tumour assessment should be performed with CT T/A/P every 12 weeks during imatinib therapy (May be extended to every 24 weeks in prolonged stable disease)

9.3 Second Line Metastatic Therapy

Options for second line treatment include high dose Imatinib 800 mg daily or Sunitinib 37.5 mg daily continuously.

Treatment will be decided on the basis of testing for exon-9 mutation:

- If the patient is exon-9 +ive then high dose imatinib 800mg daily is the option of choice (funding approval required)
- If the patient is exon-9 -ive (or if funding is not available for an exon-9 +ive patient) then Sunitinib 50mg daily for 4 of every 6 weeks will be the option of choice.

9.4 Third Line Metastatic Therapy

Regorafenib should be considered for patients' PS 0-1 who have disease progression or intolerance to imatinib and disease progression on sunitinib.

10.0 GUIDELINES ON THE MANAGEMENT OF DRUG-SPECIFIC TOXICITY

10.1 DPD Testing

Fluoropyrimidines are rapidly degraded by dihydropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or death following treatment with, for example, 5-FU or capecitabine. Homozygotes to DPD are rare (but likely to have severe toxicity or die). However, there are 3-5% of patient who are heterozygotes and are likely to develop toxicity; the clinician may reduce the fluoropyrimidine starting dose in this cohort.

The clinical recommendation of the NOG is to test all patients prior to treatment with a fluoropyrimidine.

Patients only require this genomic test to be carried out once, at the start of their first fluoropyrimidine treatment, as the results remain applicable to subsequent fluoropyrimidine cycles and future treatment regimens containing a fluoropyrimidine. Within the clinical pathway, the genomic test should be ordered for eligible patients at the point of consent for fluoropyrimidine chemotherapy or earlier if appropriate. Clinicians should follow the UK Chemotherapy Board guidance on dosing adjustments for fluoropyrimidine therapy following detection of a DPYD variant.

Work is in process to identify whether there is equitable access to this test across Kent & Medway.

The following are intended as guidelines only. Individual cases should be discussed with the relevant consultant.

10.2 Uridine Triacetate

Uridine triacetate (Vistoguard) is an antidote for management of early-onset severe or life-threatening toxicity, including diarrhoea, within 96 hours following 5FU or capecitabine administration. It is not licensed in the UK, but is available on an unlicensed basis via a 24/7 emergency ordering service, via tel. 0207 8872235.

The policy statement (link below) from NHSE contains information on inclusion / exclusion criteria and also dosing information.

https://www.england.nhs.uk/wp-content/uploads/2020/03/1929_Policy_Statement_Final_v2.pdf

11.0 APPENDIX A: CLINICAL TRIALS

Refer to the local research team who will provide on request an orientation handbook, list of current trials and associated trial protocols and summaries.

Contact numbers

MTW – Clinical Trials Office	01622 225 033
Darent Valley Hospital – Clinical Trials Office	01322 428 100 ext. 4810
Medway Hospital – Clinical Trials Office	01634 825 094
East Kent Hospitals – Clinical Trials Office:	
Solid Tumours (excluding Gynae)	01227 866 393
Gynae Clinical Trials	01843 234 343
Haematology Clinical Trials	01227 864 129

12.0 APPENDIX B: KMCC GUIDELINES ON MANAGING CARDIAC TOXICITY FOR PATIENTS RECEIVING TRASTUZUMAB

- The same monitoring modality should be used throughout the course of treatment and, where possible, this should also include the same operator, machine, and calculation algorithm. Each institution should establish a normal range for the methods used. On the basis that an echocardiogram exposes the patient to less radiation and is usually less expensive than a MUGA scan, the NOG recommend this as the method used to assess cardiac function. ECHOs are reported as a range not an absolute figure, but it is generally accepted that the lower limit of normal (LLN) for cardiac function when measured by an ECHO is 55%.
- Patients developing signs and symptoms of heart failure should have their trastuzumab treatment interrupted, have ACE inhibitor therapy initiated by the oncologist and be referred to a cardiologist. Investigation and treatment is recommended in accordance with present guidelines (NICE, 2003; Bonow et al 2005; Swedberg et al 2005).
- It is the prescriber's responsibility to check that the ECHO/MUGA is satisfactory before continuing treatment.
 - An ECHO/ MUGA should be carried out every 6 months

NB When an ECHO is used to measure cardiac function, LLN can be assumed to be 55%. For MUGA scans, the LLN for the institution should be used.

13.0 PERSONNEL AND CONTACT INFORMATION

A comprehensive, up to date list of MDM contact details can be found on the KMCC website via the following link: <http://www.KMCC.nhs.uk>

14.0 GLOSSARY

Acronyms in common usage throughout KMCC documentation

BNF	British National Formulary
BOPA	British Oncology Pharmacist Association
CNB	Cancer Network Board
COSHH	Control of substances hazardous to health regulations.
CYP	Children & Young People (in relation to the IOG)
DCCAG	Diagnostic Cross Cutting Advisory Group
DOG	Disease Orientated Group (NSSG/TSSG/TWG)
DVH	Darent Valley Hospital
DGT	Dartford and Gravesham NHS Trust
EK	East Kent
EKHUFT	East Kent Hospitals University Foundation Trust
EPS	Electronic Prescribing System
FP10(HNC)	Prescriptions issued by hospital doctors for dispensing in the community
GP	General Practitioner
HoP	High Level Operational Policy
IOSC	Improving Outcomes: A Strategy for Cancer
IV	Intravenous
K&C	Kent & Canterbury Hospital, Canterbury, (EKHUFT)
KMCC	Kent & Medway Cancer Collaborative
KMCRN	Kent & Medway Cancer Research Network
KOMS	Kent Oncology Management System
LSESN	London & South East Sarcoma Network
MFT	Medway Foundation Trust
MTW	Maidstone & Tunbridge Wells NHS Trust
NHS	National Health Service
NMP	Non-medical prescriber
NPSA	National Patient Safety agency
NOG	Non-Surgical Oncology Group <i>(Permanent oncologist sub group of the DOGs with a specific responsibility for chemo/rad pathways and advice to the DOG, Network and GEOGRAPHICAL LOCATIONS on new drugs)</i>
PoC	Pathway of Care <i>(Network agreed disease site specific clinical guidelines)</i>
QEQM	Queen Elizabeth the Queen Mother Hospital, Margate (EKHUFT)
QoL	Quality of life
QSI	Quality service information system
QST	Quality Surveillance Team
RAT	Research and Trial Group <i>(Permanent sub-group of the DOGs with a specific responsibility for taking forward the clinical trials agenda)</i>
RMH	Royal Marsden Hospital
RNOH	Royal National Orthopaedic Hospital

SACT	Systemic Anti-Cancer therapy
SACT regimen	Systemic Anti-cancer prescription on the electronic prescribing system
SACT protocol	Systemic Anti-cancer protocol on KMCC website
TTO	Treatment to take home
QVH	Queen Victoria Foundation Trust Hospital East Grinstead
UCLH	University College Hospital London
WHH	William Harvey Hospital, Ashford (EKHUFT)
WK	West Kent

15.0 DOCUMENT ADMINISTRATION

Document Title	Oncological Treatment Guidelines for Upper GI Cancer
Principle author	Caroline Waters
Co-author(s)	Upper GI NOG
Current version number	20.8.1
Current status	Draft
Agreed as “Fit for Publication” by	Mathilda Cominos NOG chair
Expected review date by	July 2022

Enquiries:	
[[1] DOG, NOG, CCG Chair [2] DOG, NOG, CCG Vice Chair	Mathilda Cominos – UGI NOG Chair Tim Sevitt Riyaz Shah

Revision History			
Date of revision	New Version Number	Nature of Revision	Confirmation of Accuracy by
December 2008 – February 2009	0.1 – 0.4	Guidelines agreed, document transposed into network guidance template, appendix A clinical trials added.	Upper GI NOG
February 2009	1	Agreed	Upper GI NOG
March 2009	1.1-1.3	Changes to sections 9 and 10	Upper GI NOG
August 2009	3.1	Changes from Dr J Waters incorporated	Sarah Wade
August 2009	4	Agreed	Upper GI NOG
February 2010	4.1	Changes agreed at the upper GI NOG	Upper GI NOG
March 2010	5	Changes agreed at the upper GI NOG	Upper GI NOG
November 2010	5.1 – 5.2	Changes agreed at upper GI NOG (sections 7.2, 2.4, appendix B)	Upper GI NOG
December 2010	6	Published	Upper GI NOG
December 2010	6.1	Section 1.1 –neo-adjuvant treatment for oesophageal cancer divided into two sections: chemotherapy and chemoradiotherapy	Upper GI NOG
February 2011	6.2	Changes agreed at the Upper GI NOG	Upper GI NOG
May 2011	7	Published	Upper GI NOG

September 2011	7.1-7.2	Changes following review at Upper GI NOG	Upper GI NOG
October 2011	8	Published	Upper GI NOG
March 2012	8.1		Upper GI NOG
March 2012	9	Published	Upper GI NOG
November 2012 – January 2013	9.1-9.2	Changes following review at the Upper GI NOG	
February 2013	10	Published	Upper GI NOG
May 2013	10.1	Draft – updated in line with NCDF & NHSE lists	
June 2013	11	Final	Upper GI NOG
November 2013- March 2014	11.1	Changes to palliative treatment options for pancreatic adenocarcinoma (section 4.3) Addition of regorafenib (section 9.4) for third line metastatic therapy for GIST	Upper GI NOG
April - May 2014	v12 – 12.2	This version was not published. Changes agreed at the UGI NOG	
June 2014	v13	Published	Upper GI NOG
October 2014	V13.1	Addition of Capecitabine & Temozolomide as a treatment option for PNET (section 8.2)	Upper GI NOG
November 2014	V14	Published	Upper GI NOG
April 2015	V14.1	Changes agreed at the UGI NOG. Revised in line with NCDF list	
September 2015	V15	Published	Tim Sevitt
November 2015	V15.1	Updated in line with published NCDF List	
January 2016	V16	Published	Tim Sevitt
March 2017 onwards	V16.1 -16.2	Addition of Irinotecan / cape to section 2.6 Addition of Gem/ Cape to section 4.1 Addition of Adjuvant chemoradiation after adjuvant chemo – section 4.2 DPD testing – statement added to section 10.1 – re: management of drug specific toxicity. Updated in line with NCDF List for: - albumin paclitaxel and gemcitabine in untreated metastatic pancreatic cancer - section 4.4 - Sorafenib in HCC section 6.2 Update to the criteria for use of Everolimus in NETS – section 8.2	
September 2017	V17	Published.	Upper GI NOG
September 2017	V17.1	Addition of FLOT regimen (section 3.1) Addition of adjuvant capecitabine for biliary tract cancer (section 5.1)	
October 2017	V18	Published	Tim Sevitt
March-Oct 2018	V18.1-V18.5	Section 2.5 Indications updated Section 2.3 Addition of Carboplatin+Paclitaxel Section 3.4 Indications updated Section 3.5 Title updated and treatment Sections 4.4/6.2/8.2/9.4 funding information updated Section 8.2 Addition of Lutetium 177 octreotate Section 14.0 web link updated	Following NOGs 13/03/2018 and 11/09/2018
NOV 2018	V19	Published	Tim Sevitt

March 2019	V19.1-19.2	Section 6.0 Addition of Lenvatinib and Regorafenib Section 4.1 Addition of adjuvant folfirinox for adjuvant pancreas Further amendment 10/09/19 change of name of protocol Section 4.1 Adjuvant modified folfirinox Section 4.4 Palliative modified folfirinox	Upper GI NOG march/sept 2019
September 2020	V20	Published	Mathilda Cominos
June 2021	V20.1-20.6	Overhaul of entire document, changes throughout each section	Changes made at UGI NOG 08.06.21
July 2021	V20.6.1-20.8.1	Updated following virtual review Addition of section 2.2.3 Addition of trastuzumab to section 2.5.1 Reformatted by R.Patel	M. Archer
July	V21	Published	M.Cominos and J.Waters